Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody

Shijun Zhu, Walter Kisiel, Yang J. Lu, Lars C. Petersen, John M. Ndungu, Terry W. Moore, Ernest T. Parker, Aiming Sun, Jann N Sarkaria, James P. Snyder, Dennis C. Liotta, Daniel J. Brat, Bassel F. El-Rayes, Mamoru Shoji

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We have developed a specific technique for imaging cancer in vivo using Cy5.5-labeled factor VIIa (fVIIa), clotting-deficient FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-tissue factor (TF) antibody. FVIIa is the natural ligand for TF. We took advantage of the fact that vascular endothelial cells (VECs) in cancer, but not normal tissue, aberrantly express TF due to its induction by vascular endothelial growth factor (VEGF). Under physiological conditions, TF is expressed by stromal cells and outer blood vessel layers (smooth muscle and adventitia), but not by VECs. We hypothesized that labeled fVIIa or anti-TF antibodies could be used to image the tumor vasculature in vivo. To test this, Cy5.5-labeled fVIIa, FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-TF antibody were developed and administered to athymic nude mice carrying xenografts including glioma U87EGFRviii, pancreatic cancer ASPC-1 and Mia PaCa-2, and squamous cell carcinoma KB-V1. Cy5.5 labeled with these targeting proteins specifically localized to the tumor xenografts for at least 14 days but unconjugated Cy5.5 did not localize to any xenografts or organs. This method of imaging TF in the tumor VECs may be useful in detecting primary tumors and metastases as well as monitoring in vivo therapeutic responses.

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalJournal of Drug Targeting
Volume23
Issue number3
DOIs
StatePublished - Apr 1 2015

Fingerprint

Factor VIIa
Thromboplastin
Antibodies
Neoplasms
Heterografts
Endothelial Cells
Paclitaxel
Nude Mice
Therapeutics
Adventitia
Protein Transport
Stromal Cells
CY5.5 cyanine dye
Pancreatic Neoplasms
Glioma
Vascular Endothelial Growth Factor A
Smooth Muscle
Blood Vessels
Squamous Cell Carcinoma
Neoplasm Metastasis

Keywords

  • Drug delivery
  • Factor VIIa inhibitor
  • Tissue factor
  • Tumor targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. / Zhu, Shijun; Kisiel, Walter; Lu, Yang J.; Petersen, Lars C.; Ndungu, John M.; Moore, Terry W.; Parker, Ernest T.; Sun, Aiming; Sarkaria, Jann N; Snyder, James P.; Liotta, Dennis C.; Brat, Daniel J.; El-Rayes, Bassel F.; Shoji, Mamoru.

In: Journal of Drug Targeting, Vol. 23, No. 3, 01.04.2015, p. 257-265.

Research output: Contribution to journalArticle

Zhu, S, Kisiel, W, Lu, YJ, Petersen, LC, Ndungu, JM, Moore, TW, Parker, ET, Sun, A, Sarkaria, JN, Snyder, JP, Liotta, DC, Brat, DJ, El-Rayes, BF & Shoji, M 2015, 'Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody', Journal of Drug Targeting, vol. 23, no. 3, pp. 257-265. https://doi.org/10.3109/1061186X.2014.988217
Zhu, Shijun ; Kisiel, Walter ; Lu, Yang J. ; Petersen, Lars C. ; Ndungu, John M. ; Moore, Terry W. ; Parker, Ernest T. ; Sun, Aiming ; Sarkaria, Jann N ; Snyder, James P. ; Liotta, Dennis C. ; Brat, Daniel J. ; El-Rayes, Bassel F. ; Shoji, Mamoru. / Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. In: Journal of Drug Targeting. 2015 ; Vol. 23, No. 3. pp. 257-265.
@article{e362c309efc24deb878fd55d491badd8,
title = "Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody",
abstract = "We have developed a specific technique for imaging cancer in vivo using Cy5.5-labeled factor VIIa (fVIIa), clotting-deficient FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-tissue factor (TF) antibody. FVIIa is the natural ligand for TF. We took advantage of the fact that vascular endothelial cells (VECs) in cancer, but not normal tissue, aberrantly express TF due to its induction by vascular endothelial growth factor (VEGF). Under physiological conditions, TF is expressed by stromal cells and outer blood vessel layers (smooth muscle and adventitia), but not by VECs. We hypothesized that labeled fVIIa or anti-TF antibodies could be used to image the tumor vasculature in vivo. To test this, Cy5.5-labeled fVIIa, FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-TF antibody were developed and administered to athymic nude mice carrying xenografts including glioma U87EGFRviii, pancreatic cancer ASPC-1 and Mia PaCa-2, and squamous cell carcinoma KB-V1. Cy5.5 labeled with these targeting proteins specifically localized to the tumor xenografts for at least 14 days but unconjugated Cy5.5 did not localize to any xenografts or organs. This method of imaging TF in the tumor VECs may be useful in detecting primary tumors and metastases as well as monitoring in vivo therapeutic responses.",
keywords = "Drug delivery, Factor VIIa inhibitor, Tissue factor, Tumor targeting",
author = "Shijun Zhu and Walter Kisiel and Lu, {Yang J.} and Petersen, {Lars C.} and Ndungu, {John M.} and Moore, {Terry W.} and Parker, {Ernest T.} and Aiming Sun and Sarkaria, {Jann N} and Snyder, {James P.} and Liotta, {Dennis C.} and Brat, {Daniel J.} and El-Rayes, {Bassel F.} and Mamoru Shoji",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/1061186X.2014.988217",
language = "English (US)",
volume = "23",
pages = "257--265",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody

AU - Zhu, Shijun

AU - Kisiel, Walter

AU - Lu, Yang J.

AU - Petersen, Lars C.

AU - Ndungu, John M.

AU - Moore, Terry W.

AU - Parker, Ernest T.

AU - Sun, Aiming

AU - Sarkaria, Jann N

AU - Snyder, James P.

AU - Liotta, Dennis C.

AU - Brat, Daniel J.

AU - El-Rayes, Bassel F.

AU - Shoji, Mamoru

PY - 2015/4/1

Y1 - 2015/4/1

N2 - We have developed a specific technique for imaging cancer in vivo using Cy5.5-labeled factor VIIa (fVIIa), clotting-deficient FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-tissue factor (TF) antibody. FVIIa is the natural ligand for TF. We took advantage of the fact that vascular endothelial cells (VECs) in cancer, but not normal tissue, aberrantly express TF due to its induction by vascular endothelial growth factor (VEGF). Under physiological conditions, TF is expressed by stromal cells and outer blood vessel layers (smooth muscle and adventitia), but not by VECs. We hypothesized that labeled fVIIa or anti-TF antibodies could be used to image the tumor vasculature in vivo. To test this, Cy5.5-labeled fVIIa, FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-TF antibody were developed and administered to athymic nude mice carrying xenografts including glioma U87EGFRviii, pancreatic cancer ASPC-1 and Mia PaCa-2, and squamous cell carcinoma KB-V1. Cy5.5 labeled with these targeting proteins specifically localized to the tumor xenografts for at least 14 days but unconjugated Cy5.5 did not localize to any xenografts or organs. This method of imaging TF in the tumor VECs may be useful in detecting primary tumors and metastases as well as monitoring in vivo therapeutic responses.

AB - We have developed a specific technique for imaging cancer in vivo using Cy5.5-labeled factor VIIa (fVIIa), clotting-deficient FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-tissue factor (TF) antibody. FVIIa is the natural ligand for TF. We took advantage of the fact that vascular endothelial cells (VECs) in cancer, but not normal tissue, aberrantly express TF due to its induction by vascular endothelial growth factor (VEGF). Under physiological conditions, TF is expressed by stromal cells and outer blood vessel layers (smooth muscle and adventitia), but not by VECs. We hypothesized that labeled fVIIa or anti-TF antibodies could be used to image the tumor vasculature in vivo. To test this, Cy5.5-labeled fVIIa, FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-TF antibody were developed and administered to athymic nude mice carrying xenografts including glioma U87EGFRviii, pancreatic cancer ASPC-1 and Mia PaCa-2, and squamous cell carcinoma KB-V1. Cy5.5 labeled with these targeting proteins specifically localized to the tumor xenografts for at least 14 days but unconjugated Cy5.5 did not localize to any xenografts or organs. This method of imaging TF in the tumor VECs may be useful in detecting primary tumors and metastases as well as monitoring in vivo therapeutic responses.

KW - Drug delivery

KW - Factor VIIa inhibitor

KW - Tissue factor

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84923382847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923382847&partnerID=8YFLogxK

U2 - 10.3109/1061186X.2014.988217

DO - 10.3109/1061186X.2014.988217

M3 - Article

VL - 23

SP - 257

EP - 265

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 3

ER -